----item----
version: 1
id: {F3A6A2AA-FD63-473A-B558-E5BB0445DAAA}
database: master
path: /sitecore/content/ScripIntelligence/Home/Test Content/Mike D Test Article
parent: {2710DB24-19F0-4CFE-99BD-AD0E787D5C95}
name: Mike D Test Article
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 17fea620-d96b-431a-b210-cabd75105893

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 36

Collaborations boost Ablynx revenues
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

Subtitle caption for the article
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 10263

<p>Ablynx can expect to gain greater value from future licensing deals, analysts predict, after its first half 2008 revenues grew significantly on the back of R&D revenues.</p>

    <blockquote class="article-pullquote">
        Sometimes you just gotta come up with something to say.
    </blockquote><p>The Belgian company reported a 36% rise in revenue to &euro;6.2 million. The increase was attributable to a &euro;1.6 million increase in R&D revenues, resulting mainly from agreements with Novartis, Wyeth, Boehringer Ingelheim and Proctor & Gamble using Ablynx's Nanobody platform.</p>    <aside class="article-sidebar">
        <h3>Will Amgen, Sandoz Tango Across Old Ground?</h3>
        <span class="article-sidebar__byline">by Donna Young</span>
        <time class="article-sidebar__date">14 Sep 2015</time>

        <p>Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.</p>
        <a class="article-sidebar__read-more" href="#">Read the full article here </a>
    </aside><p>Ablynx should expect to receive further milestones from collaborations before the end of the year, say Piper Jaffray analysts. For example, last month Ablynx and Boehringer Ingelheim extended their $265 million worldwide research and licensing agreement to develop new treatments for Alzheimer's disease for another year.</p><p>The company also plans to strengthen its own pipeline and hopes to start six to eight internal discovery programmes by the end of the year. Its lead programme ALX-0081 entered a Phase Ib study in patients undergoing percutaneous coronary infusion in May. It expects to complete the study by the end of the year and is preparing a Phase II trial. In addition, Ablynx plans to file an IND for a subcutaneous formulation of the compound, ALX-0681, by the end of 2008. Piper Jaffray says the subcutaneous delivery form is expected to be more commercially attractive.</p>    <aside class="article-inline-image">
        <img src="http://placehold.it/1200x300">
        <em>Image Source: Associated Press</em>
        <span class="article-inline-image__caption">Image caption goes here</span>
    </aside><p>Overall, Ablynx has the means to continue developing its activities in the second half, with reported cash of &euro;115.3 million, higher than Piper Jaffray's forecast of &euro;112.8 million.</p><p>Cash flow for the period rose from &euro;6.5 million to &euro;9.7 million because of a higher loss for the period and a decrease in trade payables and deferred incomes. However, it was lower than Piper Jaffray's estimate of &euro;12.1 million. And the company's net loss, up by 21% to &euro;7.5 million, was also lower than the analysts' forecast of &euro;8.5 million.</p>    <div class="article-inline-image article-inline-image--pull-right">
        <img src="http://placehold.it/1200x300">
        <em>Image Source: Associated Press</em>
        <span class="article-inline-image__caption">Image caption goes here</span>
    </div><p>R&D expenses rose by 52% to &euro;12.9 million, mainly owing to an increase in R&D staff. General and administrative costs grew by &euro;800,000 to &euro;3.4 million, following an increase in consulting and general costs.</p>    <div class="article-inline-image article-inline-image--pull-left">
        <img src="http://placehold.it/1200x300">
        <em>Image Source: Associated Press</em>
        <span class="article-inline-image__caption">Image caption goes here</span>
    </div><p>Piper Jaffray believes that the company is "a sweetspot" acquisition by big pharma, as it has platform technology, sufficient cash and links to big pharma while retaining exclusivity on several therapeutic areas and potential targets.</p>

  <table class="article-table">
        <thead>
            <tr>
                <th>Column Header</th>
                <th>Column Header</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <th colspan="2">Row Section Header</th>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <th colspan="2">Row Section Header</th>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
        </tbody>
    </table>

    <table class="article-table article-table--mobile-link">
        <thead>
            <tr>
                <th>Table</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>
                    <svg class="article-table__expand-table">
                        <use xlink:href="/dist/img/svg-sprite.svg#expand-table"></use>
                    </svg>
                    <a href="#">View full table</a>
                </td>
            </tr>
        </tbody>
    </table>

    <table class="article-table article-table--zebra">
        <thead>
            <tr>
                <th>Column Header</th>
                <th>Col Hdr</th>
                <th>Col Hdr</th>
                <th>Col Hdr</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td class="article-table__rowspan" rowspan="4">Lorem ipsum blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
        </tbody>
        <tbody>
            <tr>
                <td class="article-table__rowspan" rowspan="4">Lorem ipsum blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
        </tbody>
        <tbody>
            <tr>
                <td class="article-table__rowspan" rowspan="4">Lorem ipsum blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
            <tr>
                <td>Lorem ipsum blah blah blah</td>
                <td>Blah blah blah blah</td>
                <td>Blah blah blah blah</td>
            </tr>
        </tbody>
    </table>
<p>The French Agence de Medecine Preventive (AMP) has received $10 million from the Bill and Melinda Gates Foundation to support the development of national vaccine advisory committees across Africa and Asia.</p>   <div class="article-interview">
        <h2>Interviews and Q&amp;A</h2>

        <div class="article-interview__question">
            The quick brown fox jumped over the lazy dog. The quick brown fox jumped over the lazy dog. The quick brown fox jumped over the lazy dog.
        </div>
        <div class="article-interview__answer">
            Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
        </div>
        <div class="article-interview__question">
            The quick brown fox jumped over the lazy dog.
        </div>
        <div class="article-interview__answer">
            Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
        </div>
    </div><p>The seven-year grant will help GAVI-eligible countries establish the committees, in order to develop sustainable vaccination plans tailored to each country's specific needs.</p><p>Philippe Stoeckel, chairman of the AMP, said the need for national vaccine expertise was increasing as new inoculants being developed could soon be introduced, and poorer countries could struggle to implement the treatments if they were expensive, required new approaches to organising vaccination and had to compete for limited resources with other healthcare priorities.</p><p>Both the AMP and the International Vaccine Institute (IVI), along with the World Health Organization, will provide technical assistance and guidance for the committees, including developing decision-making protocols, on-site and distance training and an interactive website, as well as resources to help the development of the committees.</p><p>The AMP will be responsible for the implementation of the grant in Africa, whilst the IVI will oversee the project and funding in Asia.</p><p></p>


----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 176

<p>Ablynx can expect to gain greater value from future licensing deals, analysts predict, after its first half 2008 revenues grew significantly on the back of R&D revenues.</p>
----field----
field: {7526A634-C0A2-4FFE-88F8-227C9274B610}
name: Featured Image 16 9
key: featured image 16 9
content-length: 58

<image mediaid="{9E1FAC0E-A471-4381-8180-2B12AB62DBFD}" />
----field----
field: {B9FC8DAA-7B05-4595-92F4-A9D10C045CA6}
name: Featured Image Caption
key: featured image caption
content-length: 17

Caption for Image
----field----
field: {9E1CC2EB-BAB6-45EA-840A-A40A85A748EA}
name: Featured Image Source
key: featured image source
content-length: 12

Placehold.it
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 16

Navigation Title
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20080109T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20080109T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20080109T000000
----field----
field: {D1046D68-5D77-40E8-955A-6726049C7E6D}
name: Media Type
key: media type
content-length: 38

{B604F705-941D-4A7B-8DEE-D55DAB45E56F}
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 36

Collaborations boost Ablynx revenues
----field----
field: {DC4C3A27-A361-4FA3-A534-5CCACC374377}
name: Related Articles
key: related articles
content-length: 77

{C7D52FEC-CBFB-447E-8677-D580A3B03143}|{09D6196B-7390-4515-B428-78F0FAD7E01A}
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198600433
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{44D9A159-F544-46D2-A585-D8D3FDB962B4}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 3

640
----field----
field: {5083CA52-6DE6-4BE9-A1E6-30E9579E782D}
name: FactoryListableUrl
key: factorylistableurl
content-length: 38

{0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
----field----
field: {73F216E4-C244-4A3B-95EE-07D9FFD2D4F7}
name: FactoryListableDate
key: factorylistabledate
content-length: 38

{7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
----field----
field: {241B01C9-B518-4182-9B94-C40DB3FB9CB2}
name: FactoryListableSummary
key: factorylistablesummary
content-length: 38

{5BA0578F-65B7-4C22-8233-1603D698D8A4}
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160119T221708Z
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

17fea620-d96b-431a-b210-cabd75105893
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160122T193038Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
